Treatment of patients with AML
| Chemotherapy and mobilization . | CD34+ ≤ 7.16 × 106/kg (n = 613) . | CD34+ > 7.16 × 106/kg (n = 159) . | Total (n = 772) . | P . |
|---|---|---|---|---|
| No. of induction courses to reach CR1 | 568 | 154 | 722 | |
| 1 | 480 (85%) | 138 (90%) | 618 (86%) | |
| More than 1 | 88 (15%) | 16 (10%) | 104 (14%) | .11 |
| No. of consolidation courses from CR1 to collection | 490 | 121 | 611 | |
| 1 | 265 (54%) | 75 (62%) | 340 (56%) | |
| More than 1 | 225 (46%) | 46 (38%) | 271 (44%) | .11 |
| Ara-C included in mobilization | 555 | 142 | 697 | |
| 117 (21%) | 27 (19%) | 144 (21%) | .59 | |
| G-CSF used in mobilization | 555 | 142 | 697 | |
| 521 (94%) | 136 (96%) | 657 (94%) | .39 | |
| G-CSF alone | 271 (52%) | 68 (50%) | 339 (52%) | |
| G-CSF + Ara-C | 104 (20%) | 24 (18%) | 128 (19%) | |
| G-CSF + other chemotherapy | 146 (28%) | 44 (32%) | 190 (29%) |
| Chemotherapy and mobilization . | CD34+ ≤ 7.16 × 106/kg (n = 613) . | CD34+ > 7.16 × 106/kg (n = 159) . | Total (n = 772) . | P . |
|---|---|---|---|---|
| No. of induction courses to reach CR1 | 568 | 154 | 722 | |
| 1 | 480 (85%) | 138 (90%) | 618 (86%) | |
| More than 1 | 88 (15%) | 16 (10%) | 104 (14%) | .11 |
| No. of consolidation courses from CR1 to collection | 490 | 121 | 611 | |
| 1 | 265 (54%) | 75 (62%) | 340 (56%) | |
| More than 1 | 225 (46%) | 46 (38%) | 271 (44%) | .11 |
| Ara-C included in mobilization | 555 | 142 | 697 | |
| 117 (21%) | 27 (19%) | 144 (21%) | .59 | |
| G-CSF used in mobilization | 555 | 142 | 697 | |
| 521 (94%) | 136 (96%) | 657 (94%) | .39 | |
| G-CSF alone | 271 (52%) | 68 (50%) | 339 (52%) | |
| G-CSF + Ara-C | 104 (20%) | 24 (18%) | 128 (19%) | |
| G-CSF + other chemotherapy | 146 (28%) | 44 (32%) | 190 (29%) |
Description of chemotherapy induction, consolidation courses, and mobilization procedures in adult patients with AML who received autografts of peripheral blood stem cells according to the infused dose of CD34+ cells.
AML indicates acute myelocytic leukemia; CR1, first remission; Ara-C, cytosine arabinoside; and G-CSF, granulocyte colony-stimulating factor.